Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.

In May 2021, the FDA issued a new warning restricting the use of obeticholic acid in patients with advanced cirrhosis 1 . This is defined as cirrhosis with current or prior evidence of liver decompensation (e.g., encephalopathy, coagulopathy) or portal hypertension(e.g., ascites, gastroesophageal varices, or persistent thrombocytopenia).